
Russian scientists from Novosibirsk, west Siberia, have invented a device to define more precisely areas affected by cancerous tumours, a senior research official involved with the project said Wednesday.
"The device will lengthen the lives of many people and cut the number of lethal cancer cases," Kirill Belik said.
Advertisement
"At present, the most effective way to treat tumours is surgery, while chemotherapy and other forms of treatment are considered additional methods," he said.
He said that, at present, between 10 percent and 15 percent of patients with stomach cancer live for more than five years after a surgery.
"This is connected with the fact that surgeons removing damaged tissue are often unable to accurately define the affected areas, frequently concealed within healthy organs," Belik explained.
Scientists from three different medical institutes worked on the device for 15 years. Testing is due to begin in the near future, Belik said.
Source: IANS
LIN /J
"This is connected with the fact that surgeons removing damaged tissue are often unable to accurately define the affected areas, frequently concealed within healthy organs," Belik explained.
Scientists from three different medical institutes worked on the device for 15 years. Testing is due to begin in the near future, Belik said.
Source: IANS
LIN /J
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.

A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.

Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.

Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.

Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.